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Objective: A systematic review of the literature was undertaken to investigate whether
adjuvant radiotherapy and/or chemotherapeutics offered any additional benefit than surgery
alone in the treatment of Merkel Cell Carcinoma (MCC).
Methods: A PubMed, MEDLINE search was conducted between 1995 and 2013, to iden-
tify reported cases of surgically treated MCC followed by either observation, radiation, or
chemoradiation. Patient demographics and outcomes were recorded and compared in a
systematic fashion.
Results:Thirty-four studies (n=4475) were included.The median age was 73 years, median
follow up was 36 months and there was a 1.5:1 ratio of men to women. All 4475 patients had
surgery, 1975 had no further treatment, 1689 received postoperative RT, and 301 received
postoperative chemoRT. The most common site was face/head/neck, 47.8%. Stage 1 was
the most common clinical stage at diagnosis (57%). Three-year local control was 20%
(median 10%) in the observation cohort, compared to 65% (62%) with postoperative RT,
and 67% (75%) with postoperative chemoRT; these findings were statistically significant
(P <0.001). Recurrence was found to be 38% (60%) in the observation cohort, compared
to 23% (20%) with postoperative RT (P <0.001).Three-year overall survival (OS) was found
to be 56% (57%) in the observation cohort, compared to 70% (78%) with postoperative
RT and 73% (76%) with postoperative chemoRT (P <0.001). The observation cohort had
a median OS of 44 months compared with 64 months (P <0.001) in the postoperative
RT cohort. There was no statistically significant difference in any parameters assessed
between postoperative radiation and postoperative chemoradiation arms.
Conclusion: The comprehensive collection of retrospective data suggests a survival and
control benefit for postoperative radiation in MCC. No differences were noted between
adjuvant radiation and chemoradiation. This analysis indicates the need for prospective
trials with patients stratified by known prognostic factors.
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INTRODUCTION
Merkel cell carcinoma (MCC) is an aggressive cutaneous malig-
nancy that is known for its ability to metastasize, its high recur-
rence rate, and a mortality rate greater than that of melanoma.
Merkel cells, first described in 1875 by Friedrich Merkel, are
believed to be mechanoreceptors that relay information regarding
light touch and hair movement (1, 2) Controversy exists as to the
origin of these mechanoreceptors; both neural crest and epithelial
origin have been suggested (3, 20) Regardless of its embryologic
origin, its malignant transformation has devastating potential.
Merkel cell carcinoma is relatively rare, with an annual inci-
dence rate of 0.6 per 100,000 (4). It affects nearly twice as many
men as women and is more prevalent in whites than blacks, 94
and 1%, respectively (1, 4, 32). The average age of presentation
for this malignancy is 72 years (1). The mean age of prevalence
decreases dramatically, to 53 years of age, for immunocompro-
mised individuals. Individuals with CLL, HIV/AIDS, and organ
transplant recipients are at a 30, 13, and 10-fold increased risk
respectively (12, 21, 36).
Merkel cell is prevalent in sun-exposed areas, with nearly half
of all incidences occurring in the head and neck region (29).
In addition to sun-exposure, MCC has been associated with p-
53 mutations, arsenic exposure, Methoxsalen and ultraviolet-A
treatment in psoriasis, and infrared skin damage (1, 12, 13, 29,
48). Although these associations have been publicized, MCC has
its strongest association with polyomavirus, present in 80% of
cases (48).
The National Comprehensive Cancer Network (NCCN) 2013
guidelines recommend that patients with biopsy proven MCC
undergo sentinel lymph node biopsy (SLNB) and appropriate
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immuno panel with wide local excision (WLE) of the pri-
mary tumor. The NCCN 2013 guidelines (http://www.nccn.org/
professionals/physician_gls/pdf/mcc.pdf ) do not provide defini-
tive recommendations for treatment of the various clinical stages
of MCC. However, treatment options are still often based on the
clinical stage of the cancer and consist of excision, radiation ther-
apy, chemotherapy, or any combination of the three (38, 44).
Traditionally, MCC is treated surgically, followed by radiation ther-
apy in some instances although the radiosensitive nature of the
tumor is not definitively established (10, 19, 27). Radiation ther-
apy alone may be used for patients who are not surgical candidates
(38). The rationale for concomitant postoperative (chemoradia-
tion) is that MCC is known to have chemosensitive based on, high
initial response rates in metastatic settings (9, 16). Poulsen et al.
(38) however demonstrated no significant difference in survival
benefits with adjuvant chemotherapeutics compared with radia-
tion therapy alone (40). Chemotherapy is typically reserved for
patients with high risk of distant metastatic disease or those with
existing metastatic disease.
Data supports the use of a 1- to 2-cm margin for excision,
although this remains controversial (5, 6, 8, 30). Alternative sur-
gical options, such as the Moh’s micrographic surgery, are also
available. The Moh’s technique has become increasingly popular
due to its preservation of tissue, a cosmetic advantage, and has been
shown to be comparable to that of WLE (7). Due to the lack of
consensus for the treatment of MCC, a literature search was under-
taken to investigate postoperative treatment modalities for MCC.
MATERIALS AND METHODS
STUDY SELECTION
A PubMed, MEDLINE search was conducted between the years
1995–2013, to identify reported cases of surgically treated MCC.
The following keyword combinations were used: MCC, surgery,
postoperative management, combination treatment, radiation
therapy, and chemoradiation therapy. The search was limited to
studies published in English. A title and abstract review was then
performed and reports from additional secondary references were
also manually reviewed. Studies were included for their relevance
to surgery only (observation), surgery combined with postop-
erative radiotherapy (RT) and/or surgery combined with post-
operative chemoradiotherapy (chemoRT). Study types including
retrospective, prospective and case series were reviewed. Commen-
taries, editorials, and review articles were excluded. WLE, defined
as removal of the cancer accompanied by surrounding tissue, and
Moh’s micrographic surgery, defined as progressive removal of
cancer-containing skin layers until only cancer-free tissue remains,
were the majority of the surgical techniques included in this review.
In cases where radiotherapy was used, radiation was localized and
the dose was between 45 and 65 Gy (median of 50 Gy), with 3–4 cm
margins. Chemotherapeutics used in the literature include car-
boplatin, etoposide, cyclophosphamide, doxorubicin, epirubicin,
vincristine, cisplatin, capecitabine, or any combination.
DATA EXTRACTION
Patient characteristics including age, gender, size and location
of primary tumor, clinical stage, and nodal involvement were
reported. The following system was used to standardize clinical
stages: stage I indicated localized primary tumor of any size, with-
out evidence of lymph node involvement or distant metastasis;
Stage II indicated regional lymph node involvement (regional
draining lymph nodes or adjacent lymph nodes) without distant
metastasis; Stage III was evidence of distant disease. Primary treat-
ment were carefully reviewed and categorized into three modali-
ties: observation, RT, and chemoRT. Assessment of outcomes were
reviewed and reported as overall survival (OS), OS after 1 year,
after 3 years, local control (LC) after 1 year, 3 years, crude recur-
rence (including local recurrence and/or nodal/distant relapse),
time to recurrence, and toxicity.
INCLUSION CRITERIA
The following inclusion criteria were applied to each study:
• Primary tumor of MCC in any stage
• Positive or negative metastases to lymph nodes
• Lesions of any size
• Primary treatment included curative surgery (Moh’s micro-
graphic surgery or WLE) followed by observation, surgery fol-
lowed by radiation within 3 months, or surgery followed by
concurrent chemoradiation within 3 months.
EXCLUSION CRITERIA
• Unknown primary tumor
• Treatment of recurrent MCC
• Primary treatment did not include surgery
• Radiation or chemoradiotherapy used as salvage therapy
• Insufficient documentation.
STATISTICAL ANALYSIS
Treatment modalities were correlated to different outcome. T -
tests, odds ratios, and chi square testing was used when appropriate
using the software SOFA and MedCalc.
RESULTS
STUDY SELECTION
An initial search yielded 271 records from PubMed. An additional
12 secondary references were also reviewed (Figure 1). Abstract
review and manual review from an additional 12 secondary refer-
ences were performed and 34 studies (a total patient number of
n= 4475) were included for their fulfillment of inclusion criteria
listed above and relevance to the three treatment modalities of
interest (Figure 1). Out of the 34 studies, there were 31 retrospec-
tive studies (a total patient number of n= 4315); 2 studies reported
surgery combined with chemoradiotherapy (n= 46), seven stud-
ies reported treatment modalities of surgery alone vs. surgery
combined with post-op radiotherapy (n= 2220), and 22 stud-
ies reported all three treatment modalities of interests (n= 2049).
Out of the 34 studies, there were three prospective studies; two
studies evaluated post-op chemoradiotherapy only (n= 58) while
one study evaluated all three treatment modalities of interest
(n= 102). Not all cases of MCC treated by surgery could be
included in every parameter assessed.
DEMOGRAPHICS
The median age of patients included in analysis was 73 years (63–
80) for all three treatment arms and there was a 1.5:1 ratio of men
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FIGURE 1 | PRISMA (preferred reporting items for systemic reviews and meta-analysis) flow chart illustrating the identification of articles for analysis.
to women. The median follow up period was 36 months (range
7–60). All 4475 patients included in the review had surgery, 1975
patients had no further treatment (observation), 1689 received
postoperative radiotherapy (RT), and 301 received postopera-
tive chemoradiotherapy (chemoRT). The most common primary
site was the face/head/neck, representing 47.8% (n= 1327) of
all cases (Table 1). The most common clinical stage at diagno-
sis was Stage I local disease, which represented 57% (n= 2037)
of all cases, although this was not equally represented in each
cohort. Stage 1 disease represented 67% and 60% of all cases that
received observation and radiation therapy post-surgery, respec-
tively, but represented 29% of all cases that received postoperative
chemoradiotherapy. Stage 2, which indicates clinical involvement
of regional lymph nodes represented 30% overall, 39% of RT
cohort and 57% of postoperative chemoRT cohort. Report of
nodal status (clinical and histological) and treatment of regional
nodes (positive or negative) included regional or radical dissection,
biopsy, and irradiation. Most nodal treatments were dependent on
clinician preference and was inconsistent across studies.
LOCAL CONTROL AND CRUDE RECURRENCE
Local control was defined as the percentage of patients with
no evidence of disease at the primary site or regional lymph
nodes at follow up. The weighted mean for 3-year LC rate
was 20% in the observation cohort with a median of 10%.
This is compared to a median of 66% of patients achieving
LC (P < 0.001) after receiving postoperative radiation therapy.
Three-year LC rate was 67% with postoperative chemoradiation
with a median of 75% in comparison to 20% in the observa-
tion cohort (P < 0.001). Crude recurrence was defined as any
documented recurrence of neoplasm including local, nodal, or
distant metastatic recurrences anytime during the follow up
period. In the observation group, there was a 38% recurrence
rate (with a median of 60%) compared to a 23% recurrence
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Table 1 | Summary of patient demographics.
Characteristics Total/weighted mean Observation Surgery+RT Surgery+ChemoRT
Patient 4775 1975 % 1689 % 301 %
Gender
Male 2663 589 57 513 59 117 73
Female 1679 451 43 360 41 44 27
Age
Median (years) 73.0 75.1 72.1 66.1
Follow up
Median (months) 35.8 50.2 47.4 25.8
Clinical stage
I 2094 720 67 650 60 36 36
II 1006 347 33 423 39 55 54
III 276 3 0.2 2 0.2 10 10
Nodal involvement (clinical)
Positive 715 457 35 323 49 132 67
Negative 940 903 66 333 51 65 33
Location of primary tumor
Extremities 993 148 45 161 41 58 36
Face/head/neck 1327 151 46 177 45 66 41
Trunk 262 31 9 54 14 8 5
Other 197 0 0 0 0 28 18
Observation, surgery only treatment group; RT, received postoperative radiation therapy; ChemoRT, received postoperative chemoradiation therapy.
Table 2 | Outcome summary of retrospective studies.
Observation Median Surgery+RT Median Surgery+ChemoRT Median
44 64 84a
1 year Overall survival (%) 81 89 90 90 89 100
3 year Overall survival (%) 56 57 70 78 73 76
Crude recurrence (%) 38 60 23 20 22 35
Time to recurrence (months) 9 16 170
1 year Local control (%) 41 30 84 91 80 100
3 year Local control (%) 20 10 65 62 69 75
Observation, surgery only treatment group; RT, received postoperative radiation therapy; ChemoRT, received postoperative chemoradiation therapy.
aOnly one point of reference.
in of the postoperative radiotherapy group (median of 20%)
(P < 0.001) (Table 2). There was no statistically significant dif-
ference in any control or recurrence parameters assessed between
postoperative radiation and postoperative chemoradiation arms
(Table 3).
SURVIVAL
The 1-year OS was 81% with the median of 89% in the obser-
vation cohort in comparison to 90% and a median of 90%
the postoperative radiation cohort (P < 0.001). The 1-year OS
in the postoperative chemoradiation therapy cohort was 89%
(P < 0.001) in comparison to observation with a median of 100%.
The 3-year OS was 55% in observation (median of 57%) in
comparison to 70% (median of 78%) in the postoperative radia-
tion cohort (P < 0.001), and 73% (median of 76%) in postop-
erative chemoradiation cohort when compared to observation
(P < 0.001). The median OS in months was 44 months in the
Table 3 | Outcome summary of prospective studies.
Observation Surgery+RT Surgery+ChemoRT (%)
Acute toxicity – – 45
Chronic toxicity – – 17a
Crude recurrence – 42%a 31
Observation, surgery only treatment group; RT, received postoperative radiation
therapy; ChemoRT, received postoperative chemoradiation therapy.
aOnly one point of reference.
observation cohort in comparison to 64 months in the postopera-
tive radiation cohort (P < 0.001). Again there were no statistically
significant differences in any survival parameters assessed between
postoperative radiation and postoperative chemoradiation arms
(Table 3).
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SUBSET ANALYSIS
A subset analysis was performed contrasting observation and RT
treatments based on the size of the tumor; chemoRT was excluded
due to lack of data. Collected data was separated into two groups
(either <2 cm or =2 cm) based on the mean tumor size for the
study; it does not indicate that all tumors in the study were<2 cm
or =2 cm. Only studies where mean tumor size could be attained
were included in this subset analysis.
Group 1 (<2 cm) median overall survival for postopera-
tive observation group and RT group was 45.7 months and
53.9 months (P < 0.001) respectively; Group 2 (=2 cm) OS was
45 months and 63 months (P < 0.001) respectively (Figure 2). For
tumors <2 cm, the 3-year OS was 55.4% and 74.6% (P < 0.001)
for observation and postoperative radiation respectively. Similar
trends were also noted for tumors >2 cm for 3-year OS (56.4%
with observation vs. 69.8% with radiation) (Figure 3). The<2 cm
1-year local control rate (LC) was 52.9% and 89.2% (P < 0.001)
for observation and radiation, respectively; and the difference was
even more pronounced for the tumors >2 cm (38% vs. 83%).
Similarly, the 3-year LC for tumors <2 cm was 31.6% and 75.9%
(P < 0.001) for observation and radiation, respectively; compared
to 8% with observation and 64.7% with radiotherapy (P < 0.001)
for tumors >2 cm (Figure 3).
DISCUSSION
The diagnosis of MCC, made difficult by its lack of clinical symp-
toms, has devastating potential. Immunostains have contributed
greatly to earlier diagnosis of this rare cancer. Despite the mod-
ern advances in diagnostic abilities, there is little uniformity of
the treatment protocol for MCC. Surgical excision of the primary
tumor is most commonly practiced with little dispute. However,
few guidelines exist to direct treatment based on variables such as
clinical stage and size of the primary tumor. To our knowledge,
no definitive recommendations exist for the adjuvant treatment
of radiotherapy and/or chemotherapeutics. MCC is known to be a
radiosensitive cancer, though adjuvant radiotherapy is at the dis-
cretion of the treating physician. Chemotherapeutics have been
proven to have an initial response in metastatic setting (2), but its
use in the treatment of localized MCC is controversial.
This systematic review supports the use of adjuvant treatment
with surgical excision based on the retrospective data (Table 4).
The data suggests a benefit of postoperative radiation for MCC
in terms of OS. Adjuvant radiotherapy 3-year OS was 14.2%
greater for the radiotherapy arm (70.4%) than the observation
group (56.2%). Upon subset analysis, studies with an average
tumor <2 cm demonstrated a 3-year OS that was 19.2% greater
for the radiotherapy arm (74.6%) than the observation group
(55.4%). Studies with tumors =2 cm demonstrated a 3-year OS
that was 13.4% greater for the radiotherapy arm (69.8%) than the
observation group (56.4%).
Adjuvant radiotherapy and chemoradiotherapy were both
shown to be advantageous in LC compared with surgical exci-
sion alone. Three-year LC was 45.1% greater for the radiotherapy
arm (64.6%) than the observation group (19.5%). Subset analysis
demonstrated a 44.3% difference in 3-year LC for tumors <2 cm
for the radiotherapy arm (75.9%) than the observation group
(31.6%), and a 56.7% difference in 3-year LC for tumors =2 cm
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FIGURE 2 | Median overall survival of different size tumors between
observation and postoperative radiation therapy cohort.
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FIGURE 3 | Overall survival and local control of different tumor sizes
between observation and postoperative radiation therapy cohort.
Abbreviations: observation, surgery only treatment group; RT, received
postoperative radiation therapy; OS, overall survival; LC, local control.
for the radiotherapy arm (64.7%) than the observation group
(8%). These outcomes existed despite the fact that there were more
patients with later stage disease in the radiation cohort. Chemora-
diotherapy did not demonstrate any added benefits compared with
radiotherapy alone in regards to LC.
Based on the pattern that current studies reveal, we recom-
mend that a large prospective trial should be conducted to evaluate
the true effect of postoperative radiation. Adjuvant radiotherapy
was statistically significant for improvement of both OS and local
recurrence. There was no statistically significant difference in any
control or recurrence parameters assessed between postoperative
RT and postoperative chemoRT arms. Adjuvant chemoRT did
not significantly improve OS compared with radiotherapy alone.
However, analysis of the primary tumor characteristics revealed
that tumor stages and regional lymph node involvement were
not equally represented among the three treatment cohorts. In
particular, 56% of the patients receiving chemotherapy had stage
II tumor and 10% of the patients had stage III tumor; both are
significantly more common than patients receiving postoperative
radiation therapy (39 and 0.5%, respectively). Also, 65% of the
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Table 4 | Summary of age, follow up, size, nodal status, and outcome across three treatment cohort from 34 original studies.
Study PostOp Arm F/U N Age AvgSize LN+ (%) LN− (%) Crude Rec (%) 3-year LC (%) 3-year OS (%)
Field et al. (15) Observation 43.2 256 70 1.2 38 62 25 – –
Radiation 68 2.7 – –
ChemoRT 27 – – –
Senchenkov et al. (43) Observation 4.8 16 66.6 – – – 50 – –
Radiation 21 38 – –
Warner et al. (49) Observation 16 8 74 1.5 27 72 88 – –
Radiation 8 33 – –
Meeuwissen et al. (31) Observation 20 38 74 <2 – _ 100 0 65
Radiation 34 29 68 86
Ghadjar et al. (17) Observation 60 40 73 2.4 – – – 8 56
Radiation 118 62 64
ChemoRT 15 – – –
Howels et al. (22) Observation 38 53 75 1.1 29 66 – – –
Radiation 69 – – –
ChemoRT 5 – – –
Mojika et al. (33) Observation 40 689 74 2.0 – – – – 55
Radiation 477 – – 69
Ott et al. (34) Observation 37 – 68 2.0 26 74 48 – –
Radiation – 0 – 50
Poulsen et al. (40) Observation 48 0 67 >1 – – – – –
Radiation 0 – – –
ChemoRT 41 48 75 76
Akhtar et al. (2) Observation 7 5 70.3 <2 – – – – –
Radiation – – – –
Teratola et al. (47) Observation 39.6 53 70.1 2.2 43 58 – – 76
Radiation 56 – – 84
Franco et al. (30) Observation – 7 67 2.7 38 63 – – –
Radiation 7 – – –
ChemoRT 2 – – –
Boyer et al. (6) Observation 27.8 25 74 1.6 – – 52 – 92
Radiation 20 20 – 78
Clark et al. (8) Observation 27.6 36 70 1.1 – – – 65 –
Radiation 66 – 80 –
Pectaside et al. (35) Observation 24 18 68 – – – 5 10 50
Radiation 3 0 80 88
ChemoRT 1 0 – –
Jabbour et al. (24) Observation – 73 72 <2.0 37 63 – – 38
Radiation 36 – – 62
ChemoRT 9 – – –
Soult et al. (45) Observation 26 13 71.3 2.0 11 88 15 20 –
Radiation 13 23 38 –
Eich et al. (10) Observation 22 14 73 – 42 58 86 20 –
Radiation 16 62 38 –
(Continued)
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Table 4 | Continued
Study PostOp Arm F/U N Age AvgSize LN+ (%) LN− (%) Crude Rec (%) 3-year LC (%) 3-year OS (%)
Lok et al. (28) Observation 51 0 74 – 64 35 – – –
Radiation 40 10 – 70
Hui et al. (23) Observation 26 11 79 <2.0 35 65 45 – –
Radiation 165 – – –
ChemoRT 29 – – –
Allen et al. (3) Observation 40 196 69 1.5 25 75 14 – –
Radiation 41 8 – –
Poulsen et al. (42) Observation 26 0 67.5 – 77 22 – – –
Radiation 0 – – –
ChemoRT 50 44 – –
Wobser et al. (50) Observation – – 80 – 40 60 – – –
Radiation 1 – – –
ChemoRT 4 60 0 –
Poulsen et al. (39) Observation 22 0 67 <2.0 65 35 – – –
Radiation 0 – – –
ChemoRT 40 – – –
Poulsen et al. (37, 41) Observation 56 17 76 – – – 10 –
Radiation 29 – 40 –
ChemoRT 6 – – –
Kim et al. (25) Observation – 269 77 <2.0 – – – – –
Radiation 269 – – –
Lawenda et al. (26) Observation – 5 68.8 <2.0 33 67 60 – –
Radiation 3 0 – –
ChemoRT 1 100 – –
Poulsen et al. (37) Observation 0 – 55 45 – – –
Radiation 41.5 62 72.5 42 – –
ChemoRT 29.5 40 67 25 – –
Tai et al. (46) Observation 25 21 77 <2.0 – – 67 – –
Radiation 3 – – –
ChemoRT 1 – – –
Fenig et al. (11, 14) Observation – 15 63 3.0 – – 80 – –
Radiation 4 9 – –
Eng et al. (14) Observation 39.6 15 69 – – – – – 58
Radiation 4 41 – –
Boyle et al. (7) Observation 36 17 68 – – – 71 – –
Radiation 10 – – –
Gillenwater et al. (18) Observation – 34 68.4 <2.0 – – 97 – –
Radiation 26 50 – –
Wong et al. (51) Observation – 16 80 <2.0 – – 94 – –
Radiation 11 0 – –
ChemoRT 1 – 100 100
Observation, surgery only treatment group; RT, received postoperative radiation therapy; ChemoRT, received postoperative chemoradiation therapy; F/U, follow up;
LN, regional lymph node involvement; OS, overall survival; LC, local control.
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chemoRT patients were positive for clinical nodal involvement,
compared to 35% in the overall cohort. In this review, chemoRT
group had significantly fewer points of reference (n= 301) than
the RT group (n= 1689). Chemotherapeutics may play a role
in more advanced MCC, though limited data makes their role
unproven. ChemoRT should also be considered in patients who
are unresponsive to radiotherapy alone. Addition of chemother-
apeutics should be used cautiously due to its toxicity. ChemoRT
was shown to have statistically significant increase in both acute
(P = 0.002) and chronic (P < 0.001) toxicity when compared with
radiotherapy alone.
Merkel cell carcinoma is a cancer that has great metastasis
potential. Though some physicians use size as a factor in determin-
ing the use of adjuvant treatments, no definitive guidelines have
been published. In this review, we compared the mean primary
tumor size among various publications. We separated all studies
into one of two groups; Group 1 had a mean tumor size <2 cm
and Group 2 had a mean tumor size =2 cm. This division has a
major limitation; the groups are based on the mean of the study,
not the mode. This division may skew the size of the majority
of that study secondary to a few extremely large tumors. Though
this classification system is not ideal, the results of this review
support the use of radiotherapy regardless of tumor size. Mojika
and colleagues (33) analyzed retrospective data from 1665 patient
from the National Cancer Institute; this data suggested that overall
median survival in months of patients were improved through the
use of adjuvant radiation therapy in comparison to surgery alone,
despite the size of the primary tumor. They further suggest that
survival improvement was most prominent when primary tumors
are larger than 2 cm.
Future research endeavors warrant comparison of radiother-
apy and chemoradiotherapy adjuvants for advance stage MCC.
This comparison will directly show if there is any added bene-
fit to chemotherapeutics. Furthermore, it will also establish data
from which recommendations for adjuvant treatments may be
established based on clinical staging. Current study did not yield
enough well documented cases to compare the two cohort directly.
While this comprehensive retrospective analysis in a broad patient
population reflects an advantage for postoperative radiation, there
could be certain prognostic factors in a given patient that may
favor surgery alone. Many variables may play a role in the success
of treatment for MCC. Primary tumor size, nodal involvement
and presence of metastasis should be recorded for points of data
for future research. These variables may play a critical role in the
establishment of treatment guidelines for MCC as well.
This review has several limitations; mostly a product of the ret-
rospective nature of the studies included which is insufficient basis
to recommend standard of care. Poulsen conducted the only three
prospective studies conducted on postoperative management of
MCC, and they all addressed adjuvant chemoradiation against
adjuvant radiation alone (37, 39, 42). No randomized trial has ever
been conducted regarding the role of radiation in MCC and the
current clinical trials all address the use of certain immunothera-
pies that have been successful in other skin cancers. Although we
attempted to make cohorts similar through certain subset analyses,
a true comparison of outcomes of patients with the same stage,
tumor size, or nodal involvement could not be accomplished due
to a lack of original patient data. The trend identified by current
study support the use of postoperative radiation for MCC. The
data on postoperative chemoradiation, on the other hand, was
restricted enough by the studies limitations so that no trend could
be discovered.
CONCLUSION
This systematic review demonstrates that the use of adjuvant
radiotherapy in the treatment of MCC, regardless of tumor size,
location, or nodal involvement, resulted in survival and control
benefit reported in the literature. However, standard documen-
tation of retrospective data and large scale prospective studies
are needed to consolidate current trend. The use of adjuvant
chemoradiotherapy remains unproven, although there may be a
benefit in systemic disease. Establishment of treatment guidelines
is needed.
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